Bexsero® chronicle

References

• Ehreth J. The global value of vaccination. Vaccine. 2003;21(7–8):596–600.
   PubMed Web of Science ®Google Scholar
• Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, et al. Accelerating next-generation vaccine development for global disease prevention. Science. 2013;340(6136):1232910.
   PubMed Web of Science ®Google Scholar
• Anonymous. Epidemics of meningococcal disease. African meningitis belt, 2001. Wkly Epidemiol. 2000;76(37):282–8.
   Google Scholar
• Vieusseux M. Mémoire sur la maladie qui a regné a Genêve au printemps de 1805. J Med Chir Pharm. 1805;11:163–82.
   Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Canada Commun Dis Rep (CCDR). 2007;33:1–15.
   Google Scholar
• Ines Agudelo C, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis. 2008;14(6):990–1.
   PubMed Web of Science ®Google Scholar
• Ciccone FH, Suzuki E, Pellini AC. Meningococcal disease: communitarian outbreak investigation in Grajau, in the city of Sao Paulo. BEPA. 2006;3:7–12.
   Google Scholar
• Chiavetta L, Chavez E, Ruzic A, Mollerach M, Regueira M. [Surveillance of Neisseria meningitidis in Argentina, 1993–2005: distribution of serogroups, serotypes and serosubtypes isolated from invasive disease]. Rev Argent Microbiol. 39(1):21–7. Spanish.
   PubMedGoogle Scholar
• Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol. 2005;43(10):5129–35.
   PubMed Web of Science ®Google Scholar
• Coulson GB, von Gottberg A, du Plessis M, Smith AM, de Gouveia L, Klugman KP, et al. Meningococcal disease in South Africa, 1999–2002. Emerg Infect Dis. 2007;13(2):273–81.
   PubMed Web of Science ®Google Scholar
• Chiou CS, Liao JC, Liao TL, Li CC, Chou CY, Chang HL, et al. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis. 2006;6:25.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kuroki T, Watanabe Y, Tanaka H, Inouye H, Yamai S, et al. Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing. J Med Microbiol. 2004;53(Pt 7):657–62.
   PubMed Web of Science ®Google Scholar
• Australian Meningococcal Surveillance Programme. CDI. 2007;31:185–93.
   Google Scholar
• Black S, Pizza M, Nissum M, Rappuoli R. Toward a meningitis-free world. Sci Transl Med. 2012;4(123):123ps125.
   Web of Science ®Google Scholar
• Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31(1):3–14.
   PubMed Web of Science ®Google Scholar
• Atkinson W, Wolfe S, Hamborsky J, editors. Centers for Disease Control and Prevention meningococcal disease. The pink book: epidemiology and prevention of vaccine-preventable diseases. 12th ed. Washington, DC: Public Health Foundation; 2011.
   Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403.
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378–88.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm: ECDC; 2011.
   Google Scholar
• World Health Organization. Meningococcal meningitis factsheet. Geneva: WHO; 2010.
   Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134(3):556–66.
   PubMed Web of Science ®Google Scholar
• Virji M. Meningococcal disease: epidemiology and pathogenesis. Trends Microbiol. 1996;4(12):466–9; discussion 469–70.
   PubMed Web of Science ®Google Scholar
• Coutinho A, Moller G. Mitogenic properties of the thymus-independent antigen pneumococcal polysaccharide S3. Eur J Immunol. 1973;3(10):608–13.
   PubMed Web of Science ®Google Scholar
• Swain CL, Martin DR. Survival of meningococci outside of the host: implications for acquisition. Epidemiol Infect. 2007;135(2):315–20.
   PubMed Web of Science ®Google Scholar
• Azurmendi HF, Vionnet J, Wrightson L, Trinh LB, Shiloach J, Freedberg DI. Extracellular structure of polysialic acid explored by on cell solution NMR. Proc Natl Acad Sci USA. 2007;104(28):11557–61.
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–7.
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138(12):4402–7.
   PubMed Web of Science ®Google Scholar
• Isomura R, Kitajima K, Sato C. Structural and functional impairments of polysialic acid by a mutated polysialyltransferase found in schizophrenia. J Biol Chem. 2011;286(24):21535–45.
   PubMed Web of Science ®Google Scholar
• Budroni S, Siena E, Dunning Hotopp JC, Seib KL, Serruto D, Nofroni C, et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci USA. 2011;108(11):4494–9.
   PubMed Web of Science ®Google Scholar
• Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host–pathogen interaction. Genes Dev. 2005;19(22):2645–55.
   PubMed Web of Science ®Google Scholar
• Mayrand D, Grenier D. Biological activities of outer membrane vesicles. Can J Microbiol. 1989;35(6):607–13.
   PubMed Web of Science ®Google Scholar
• Zhou L, Srisatjaluk R, Justus DE, Doyle RJ. On the origin of membrane vesicles in Gram-negative bacteria. FEMS Microbiol Lett. 1998;163(2):223–8.
   PubMed Web of Science ®Google Scholar
• Pettit RK, Judd RC. The interaction of naturally elaborated blebs from serum-susceptible and serum-resistant strains of Neisseria gonorrhoeae with normal human serum. Mol Microbiol. 1992;6(6):729–34.
   PubMed Web of Science ®Google Scholar
• Craven DE, Peppler MS, Frasch CE, Mocca LF, McGrath PP, Washington G. Adherence of isolates of Neisseria meningitidis from patients and carriers to human buccal epithelial cells. J Infect Dis. 1980;142(4):556–68.
   PubMed Web of Science ®Google Scholar
• Stephens DS, Edwards KM, Morris F, McGee ZA. Pili and outer membrane appendages on Neisseria meningitidis in the cerebrospinal fluid of an infant. J Infect Dis. 1982;146(4):568.
   PubMed Web of Science ®Google Scholar
• Namork E, Brandtzaeg P. Fatal meningococcal septicaemia with “blebbing” meningococcus. Lancet. 2002;360(9347):1741.
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Boslego J, Frøholm LO, Ray JS, Moran EE, Brandt BL. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie van Leeuwenhoek. 1987;53(6):403–11.
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Mandrell RE, Altieri P, Berman S, Lowenthal J, Artenstein MS. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis. 1978;137(6):728–39.
   PubMed Web of Science ®Google Scholar
• Helting TB, Guthohrlein G, Blackkolb F, Ronneberger H. Serotype determinant protein of Neisseria meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol Microbiol Scand Sect C Immunol. 1981;89(2):69–78.
   PubMedGoogle Scholar
• Frasch CE, Robbins JD. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med. 1978;147(3):629–44.
   PubMed Web of Science ®Google Scholar
• Arnold R, Galloway Y, McNicholas A, O’Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29(40):7100–6.
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207; discussion 208–10.
   PubMedGoogle Scholar
• Rosenqvist E, Høiby EA, Wedege E, Bryn K, Kolberg J, Klem A, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 1995;63(12):4642–52.
   PubMed Web of Science ®Google Scholar
• Sotolongo F, Campa C, Casanueva V, Fajardo EM, Cuevas IE, González N. Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application. MEDICC Rev. 2007;9(1):16–22.
   PubMedGoogle Scholar
• Holst J, Nokleby H, Bettinger JA. Considerations for controlling invasive meningococcal disease in high income countries. Vaccine. 2012;30(Suppl 2):B57–62.
   Google Scholar
• Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3–12.
   Google Scholar
• van der Voort ER, van Dijken H, Kuipers B, van der Biezen J, van der Ley P, Meylis J, et al. Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect Immun. 1997;65(12):5184–90.
   PubMed Web of Science ®Google Scholar
• Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J. 1997;42(4):118–21.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Mandl CW, Black S, de Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol. 2011;11(12):865–72.
   PubMed Web of Science ®Google Scholar
• Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995;269(5223):496–512.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445–50.
   PubMed Web of Science ®Google Scholar
• Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science. 2005;309(5731):148–50.
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816–20.
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccines Immunother. 2012;8(2):174–83.
   PubMed Web of Science ®Google Scholar
• Bambini S, Piet J, Muzzi A, Keijzers W, Comandi S, De Tora L, et al. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One. 2013;8(5):e65043.
   Web of Science ®Google Scholar
• Bexsero (summary of product characteristics). Siena: Novartis Vaccines and Diagnostics S.r.l.; 2013.
   Google Scholar
• Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71–9.
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–82.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–35.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416–25.
   PubMed Web of Science ®Google Scholar
• Data on file. Emeryville, CA: Novartis Vaccines and Diagnostics.
   Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–5.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–74.
   PubMed Web of Science ®Google Scholar
• EMA. Authorization Details for Bexsero. Available from: http://www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/002333/human_med_001614.jsp&mid = WC0b01ac058001d124
   Google Scholar
• Health Canada. Bexsero. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_bexsero_147275-eng.php
   Google Scholar
• Australian Government: Department of Health: Therapeutic Goods Administration. Available from: http://www.tga.gov.au/pdf/auspar/auspar-meningococcal-131031.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Princeton University meningococcal disease outbreak. December 2013. Available from: http://www.cdc.gov/meningococcal/outbreaks/princeton.html
   Google Scholar
• Centers for Disease Control and Prevention. University of California, Santa Barbara meningococcal disease outbreak. January 2014. Available from: http://www.cdc.gov/meningococcal/outbreaks/ucsb.html
   Google Scholar
• US Food and Drug Administration. Frequently asked questions: breakthrough therapies. Available from: http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/fdasia/ucm341027.htm
   Google Scholar
• Wise J. Meningitis B vaccine to be introduced in UK after U turn on its cost effectiveness. BMJ. 2014;348:g2327.
   Web of Science ®Google Scholar
• Madhavan G, Sangha K, Phelps C, Fryback D, Rappuoli R, Martinez RM, King L, editors. Ranking vaccines: a prioritization software tool: phase II: prototype of a decision-support system. Washington, DC: National Academy of Sciences; 2013.
   Google Scholar
• Hinman AR. Global progress in infectious disease control. Vaccine. 1998;16(11–12):1116–21.
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244–56.
   PubMed Web of Science ®Google Scholar